PM&R
Volume 1, Issue 6 , Pages 516-523, June 2009

The Effectiveness of Locomotor Therapy Using Robotic-Assisted Gait Training in Subacute Stroke Patients: A Randomized Controlled Trial

  • Isabella Schwartz, MD

      Affiliations

    • Department of Physical Medicine and Rehabilitation, Hadassah University Hospital, Jerusalem, Israel
  • ,
  • Anna Sajin, MD

      Affiliations

    • Department of Physical Medicine and Rehabilitation, Hadassah University Hospital, Jerusalem, Israel
  • ,
  • Iris Fisher, MScPT

      Affiliations

    • Department of Physical Medicine and Rehabilitation, Hadassah University Hospital, Jerusalem, Israel§
  • ,
  • Martin Neeb, BPT

      Affiliations

    • Department of Physical Medicine and Rehabilitation, Hadassah University Hospital, Jerusalem, Israel
  • ,
  • Mara Shochina, MD

      Affiliations

    • Department of Physical Medicine and Rehabilitation, Hadassah University Hospital, Jerusalem, Israel
  • ,
  • Michal Katz-Leurer, PhD

      Affiliations

    • Physical Therapy Department, School of Health Professions, Tel-Aviv University, Ramat-Aviv, Israel#
  • ,
  • Zeev Meiner, MD

      Affiliations

    • Department of Physical Medicine and Rehabilitation, Hadassah University Hospital, P.O.B. 24035 Mount Scopus, Jerusalem, Israel⁎⁎
    • Corresponding Author InformationAddress correspondence to Z.M.

Received 7 September 2008; accepted 16 March 2009.

Objective

To evaluate the effectiveness of early and prolonged locomotor treatment with the use of a robotic-assisted gait training (RAGT) device (Lokomat; Hocoma Inc., Zurich, Switzerland) on the functional outcomes of patients after subacute stroke.

Design

A nonblinded prospective, randomized, controlled study.

Setting

Rehabilitation department in tertiary university medical center.

Patients

Sixty-seven patients in the first 3 months after subacute stroke were randomized into 2 groups as follows. Thirty-seven patients were treated with RAGT, and 30 were treated with regular physiotherapy. Inclusion criteria were first stroke, independent ambulation before the stroke, and neurological severity between 6 and 20 according to the National Institutes of Health Stroke Scale (NIHSS).

Intervention

RAGT treatment was administered 3 times a week for 30 minutes, combined with regular physiotherapy for 6 weeks. Control patients received the equivalent additional time of regular physiotherapy.

Main outcome measurements

The primary outcome was the ability to walk independently, as assessed by use of the functional ambulatory capacity scale. The secondary outcomes included the neurological status according to the NIHSS; functional motor assessment (determined by use of the stroke activity scale); and gait parameters, including gait velocity, endurance, and number of climbed stairs.

Results

In the intention-to-treat analysis, subjects in the RAGT group exhibited greater gains than the control group in their ability to walk independently, as expressed by a greater functional ambulatory capacity score (P < .01), and in their neurological status according to NIHSS (P < .01). Among those who achieved independent walking, nonsignificant differences between groups were noted according to secondary outcome measures of gait parameters except from step climbing.

Conclusion

This controlled study showed, at the end of a 6-week trial, that locomotor therapy with the use of RAGT combined with regular physiotherapy produced promising effects on functional and motor outcomes in patients after subacute stroke as compared with regular physiotherapy alone.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 
  •  Disclosure: nothing to disclose
  •  Disclosure: nothing to disclose
  • § Disclosure: nothing to disclose
  •  Disclosure: nothing to disclose
  •  Disclosure: nothing to disclose
  • # Disclosure: nothing to disclose
  • ⁎⁎ Disclosure: nothing to disclose

 Disclosure Key can be found on the Table of Contents and at www.pmrjournal.org

PII: S1934-1482(09)00343-8

doi:10.1016/j.pmrj.2009.03.009

PM&R
Volume 1, Issue 6 , Pages 516-523, June 2009